Cinacalcet: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Cinacalcet. Educational only — not medical advice.
Labeled uses
Sensipar® is indicated for the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease on dialysis. Sensipar® is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.
Source: FDA labeling via NIH DailyMed (set 8f390187…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.